GLP1R and metabolic dysfunction-associated steatohepatitis: For example, the GLP-1R agonist semaglutide received accelerated FDA approval in August 2025 for the treatment of MASH with moderate fibrosis (F2–F3), but it is to be used in conjunction with lifestyle interventions of calorie restriction and exercise.